The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cardiac Biomarkers-Global Market Insights and Sales Trends 2024
Synopsis
Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
The global Cardiac Biomarkers market size is expected to reach US$ 1315.7 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029. The market is mainly driven by the significant applications of Cardiac Biomarkers in various end use industries. The expanding demands from the Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure and Others, are propelling Cardiac Biomarkers market. Troponin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CK-MB segment is estimated at % CAGR for the next seven-year period.
The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cardiac Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cardiac Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cardiac Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cardiac Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cardiac Biomarkers covered in this report include Abbott, Abbott, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMérieux and Bio-Rad Laboratories, etc.
The global Cardiac Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Abbott
F. Hoffmann-La Roche
Advanced ImmunoChemical
AgPlus Diagnostics
BG Medicine
BioLegend
bioMérieux
Bio-Rad Laboratories
BODITECH MED
Global Cardiac Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cardiac Biomarkers market, Segment by Type:
Troponin
CK-MB
Natriuretic Peptides - BNP and NT-proBNP
Myoglobin
Others
Global Cardiac Biomarkers market, by Application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cardiac Biomarkers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia. The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.
The global Cardiac Biomarkers market size is expected to reach US$ 1315.7 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029. The market is mainly driven by the significant applications of Cardiac Biomarkers in various end use industries. The expanding demands from the Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure and Others, are propelling Cardiac Biomarkers market. Troponin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the CK-MB segment is estimated at % CAGR for the next seven-year period.
The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cardiac Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cardiac Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cardiac Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cardiac Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cardiac Biomarkers covered in this report include Abbott, Abbott, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMérieux and Bio-Rad Laboratories, etc.
The global Cardiac Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Abbott
F. Hoffmann-La Roche
Advanced ImmunoChemical
AgPlus Diagnostics
BG Medicine
BioLegend
bioMérieux
Bio-Rad Laboratories
BODITECH MED
Global Cardiac Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cardiac Biomarkers market, Segment by Type:
Troponin
CK-MB
Natriuretic Peptides - BNP and NT-proBNP
Myoglobin
Others
Global Cardiac Biomarkers market, by Application
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cardiac Biomarkers companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cardiac Biomarkers
1.1 Cardiac Biomarkers Market Overview
1.1.1 Cardiac Biomarkers Product Scope
1.1.2 Cardiac Biomarkers Market Status and Outlook
1.2 Global Cardiac Biomarkers Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cardiac Biomarkers Market Size by Region (2018-2029)
1.4 Global Cardiac Biomarkers Historic Market Size by Region (2018-2023)
1.5 Global Cardiac Biomarkers Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cardiac Biomarkers Market Size (2018-2029)
1.6.1 North America Cardiac Biomarkers Market Size (2018-2029)
1.6.2 Europe Cardiac Biomarkers Market Size (2018-2029)
1.6.3 Asia-Pacific Cardiac Biomarkers Market Size (2018-2029)
1.6.4 Latin America Cardiac Biomarkers Market Size (2018-2029)
1.6.5 Middle East & Africa Cardiac Biomarkers Market Size (2018-2029)
2 Cardiac Biomarkers Market by Type
2.1 Introduction
2.1.1 Troponin
2.1.2 CK-MB
2.1.3 Natriuretic Peptides - BNP and NT-proBNP
2.1.4 Myoglobin
2.1.5 Others
2.2 Global Cardiac Biomarkers Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cardiac Biomarkers Historic Market Size by Type (2018-2023)
2.2.2 Global Cardiac Biomarkers Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cardiac Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cardiac Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cardiac Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cardiac Biomarkers Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cardiac Biomarkers Revenue Breakdown by Type (2018-2029)
3 Cardiac Biomarkers Market Overview by Application
3.1 Introduction
3.1.1 Acute Coronary Syndrome
3.1.2 Myocardial Infarction
3.1.3 Congestive Heart Failure
3.1.4 Others
3.2 Global Cardiac Biomarkers Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cardiac Biomarkers Historic Market Size by Application (2018-2023)
3.2.2 Global Cardiac Biomarkers Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cardiac Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cardiac Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cardiac Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cardiac Biomarkers Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cardiac Biomarkers Revenue Breakdown by Application (2018-2029)
4 Cardiac Biomarkers Competition Analysis by Players
4.1 Global Cardiac Biomarkers Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cardiac Biomarkers as of 2022)
4.3 Date of Key Players Enter into Cardiac Biomarkers Market
4.4 Global Top Players Cardiac Biomarkers Headquarters and Area Served
4.5 Key Players Cardiac Biomarkers Product Solution and Service
4.6 Competitive Status
4.6.1 Cardiac Biomarkers Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott
5.1.1 Abbott Profile
5.1.2 Abbott Main Business
5.1.3 Abbott Cardiac Biomarkers Products, Services and Solutions
5.1.4 Abbott Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Recent Developments
5.2 Abbott
5.2.1 Abbott Profile
5.2.2 Abbott Main Business
5.2.3 Abbott Cardiac Biomarkers Products, Services and Solutions
5.2.4 Abbott Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Recent Developments
5.3 F. Hoffmann-La Roche
5.3.1 F. Hoffmann-La Roche Profile
5.3.2 F. Hoffmann-La Roche Main Business
5.3.3 F. Hoffmann-La Roche Cardiac Biomarkers Products, Services and Solutions
5.3.4 F. Hoffmann-La Roche Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.3.5 Advanced ImmunoChemical Recent Developments
5.4 Advanced ImmunoChemical
5.4.1 Advanced ImmunoChemical Profile
5.4.2 Advanced ImmunoChemical Main Business
5.4.3 Advanced ImmunoChemical Cardiac Biomarkers Products, Services and Solutions
5.4.4 Advanced ImmunoChemical Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.4.5 Advanced ImmunoChemical Recent Developments
5.5 AgPlus Diagnostics
5.5.1 AgPlus Diagnostics Profile
5.5.2 AgPlus Diagnostics Main Business
5.5.3 AgPlus Diagnostics Cardiac Biomarkers Products, Services and Solutions
5.5.4 AgPlus Diagnostics Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.5.5 AgPlus Diagnostics Recent Developments
5.6 BG Medicine
5.6.1 BG Medicine Profile
5.6.2 BG Medicine Main Business
5.6.3 BG Medicine Cardiac Biomarkers Products, Services and Solutions
5.6.4 BG Medicine Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.6.5 BG Medicine Recent Developments
5.7 BioLegend
5.7.1 BioLegend Profile
5.7.2 BioLegend Main Business
5.7.3 BioLegend Cardiac Biomarkers Products, Services and Solutions
5.7.4 BioLegend Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.7.5 BioLegend Recent Developments
5.8 bioMérieux
5.8.1 bioMérieux Profile
5.8.2 bioMérieux Main Business
5.8.3 bioMérieux Cardiac Biomarkers Products, Services and Solutions
5.8.4 bioMérieux Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.8.5 bioMérieux Recent Developments
5.9 Bio-Rad Laboratories
5.9.1 Bio-Rad Laboratories Profile
5.9.2 Bio-Rad Laboratories Main Business
5.9.3 Bio-Rad Laboratories Cardiac Biomarkers Products, Services and Solutions
5.9.4 Bio-Rad Laboratories Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.9.5 Bio-Rad Laboratories Recent Developments
5.10 BODITECH MED
5.10.1 BODITECH MED Profile
5.10.2 BODITECH MED Main Business
5.10.3 BODITECH MED Cardiac Biomarkers Products, Services and Solutions
5.10.4 BODITECH MED Cardiac Biomarkers Revenue (US$ Million) & (2018-2023)
5.10.5 BODITECH MED Recent Developments
6 North America
6.1 North America Cardiac Biomarkers Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cardiac Biomarkers Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cardiac Biomarkers Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cardiac Biomarkers Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cardiac Biomarkers Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cardiac Biomarkers Market Dynamics
11.1 Cardiac Biomarkers Industry Trends
11.2 Cardiac Biomarkers Market Drivers
11.3 Cardiac Biomarkers Market Challenges
11.4 Cardiac Biomarkers Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
